Entering text into the input field will update the search result below

NRx Pharma fails to win FDA clearance for COVID therapy

Jul. 01, 2022 7:53 AM ETNRx Pharmaceuticals, Inc. (NRXP)By: Dulan Lokuwithana, SA News Editor1 Comment

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Clinical-stage Pharma NRx Pharmaceuticals (NASDAQ:NRXP) announced on Friday that the FDA declined to issue the Emergency Use Authorization (EUA) for its COVID-19 therapy Zyesami (aviptadil).
  • NRx (NRXP) had sought FDA nod for Zyesami

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

sts66 profile picture
I thought the FDA shot them down a couple weeks ago?
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.